But now Alnylam is to abandon revusiran, its second most advanced candidate after 18 patients in the treatment arm of a phase 2 trial died, a much higher rate than those taking placebo.

The approval of Onpattro significantly derisked Alnylam's technology platform, and we don't see any lingering risks from previous issues, which includes the discontinuation of revusiran for ...

The story of Alnylam and RNA interference has been pretty ... up and we had to stop the Phase 3 study for a program called revusiran. That was due to a safety imbalance and mortality, specifically ...

Alnylam’s stock price soared more than 20% on the news. The firm earlier experienced setbacks for two other RNAi drugs, revusiran and fitusiran.

In October last year, Alnylam Pharmaceuticals’ share price was in free fall following a decision to scrap a Phase 3 clinical trial for its revusiran therapeutic for hemophilia in the wake of a ...

Last year, Alnylam scrapped the development of a third RNAi drug, revusiran, because of safety issues, including an unacceptable number of patient deaths in a phase 3 study.

Alnylam (Nasdaq: ALNY) on Wednesday released the results of its investigation into the deaths of older patients with heart problems who took revusiran, a potential treatment for a deadly inherited ...

Just three months ago, gene-silencing specialist Alnylam was pummelled after deaths in a phase 3 clinical trial forced it to abandon its revusiran candidate for hereditary ATTR amyloidosis.

On October 4, Alnylam Pharmaceuticals discontinued development of revusiran, its RNA interference (RNAi) therapeutic for treating transthyretin amyloidosis with cardiomyopathy, one of the two main ...

October was a bad month for Alnylam. Its shares plunged almost 50 percent after it abruptly scrapped its Phase 3 candidate revusiran, citing a disproportionate number of deaths in the active arm ...

It's something about revusiran's target or ATTR amyloidosis, so two of Alnylam's pipeline targets, patisiran and ALN-TTRsc02, that are designed to knockdown the same protein could be affected.

RNA interference (RNAi) company Alnylam Pharmaceuticals has discontinued one of its lead programmes, halting the development of phase III candidate revusiran due to an “imbalance of mortality”.